Targetable genetic alterations in mTCL. (A) Oncoprint of the 30 most recurrently altered genes across different subtypes of mature T-cell neoplasms among 1825 patients. (B-C) Results of the MTB-Report tool: drugs with proposed sensitivity (B) or resistance (C) based on genetic alterations of the indicated, affected genes. Shown in panels B-C are suggestions that occurred in at least 5% of the patients. AITL, angioimmunoblastic T-cell lymphoma; ALK^– ALCL, anaplastic large cell lymphoma without ALK translocation; ALK⁺ ALCL, anaplastic large cell lymphoma with ALK translocation; ATLL, adult T-cell leukemia/lymphoma; CTCL, cutaneous T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; HS-TCL, hepatosplenic T-cell lymphoma; NKT, NK/T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified.